IOVA · Iovance Biotherapeutics, Inc.

📣 What IOVA Says Is Next

• 1H27 · “Multiple patients have been treated for cutaneous squamous cell carcinoma (CSCC) and Merkel cell carcinoma (MCC) with initial data expected in 1H27.”
  Company press release, Aug 6, 2026 · SEC filing
• 4Q26 · “Enrollment is nearly complete in the pivotal cohorts and program updates are expected in 4Q26.”
  Company press release, Aug 6, 2026 · SEC filing
• 1H27 · “Advanced melanoma causes more than 2,500 deaths annually in the UK. · Switzerland: Potential approval of the MAA in Switzerland is expected in 1H27, opening a second market opportunity in Europe with the potential for medical tourism.”
  Company press release, Aug 6, 2026 · SEC filing

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

🧪 Trial & FDA Catalysts

• Oct 2026 · Phase 1/2 · Recruiting · E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associa
  Registry primary completion date, not a results date
• Jan 2027 · Phase 2 · Recruiting · E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
  Registry primary completion date, not a results date
• Apr 2027 · Phase 2 · Active Trial · LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Tripl
  Registry primary completion date, not a results date
• May 2027 · Phase 1 · Recruiting · A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleom
  Registry primary completion date, not a results date
• Sep 2027 · Phase 1/2 · Recruiting · A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Partici
  Registry primary completion date, not a results date
• Nov 2027 · Phase 1 · Active Trial · A Study of LN-144 in People With Metastatic Melanoma to the Brain
  Registry primary completion date, not a results date

📊 Drug Pipeline

Also used in these trials (approved or third-party drugs, not IOVA's own candidates): Pembrolizumab, Ipilimumab, Nivolumab, Nivolumab And Relatlimab-Rmbw, Paclitaxel, Pemetrexed Disodium, Aldesleukin, Carboplatin, Cisplatin, Durvalumab, Interleukin-2, Mesna.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

IOVA holds $358.8M in cash and short-term investments (as of Jun 30, 2026) and burns about $66.5M/quarter from operations, an estimated runway of 16.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 57 · Elevated

• Cash runway 16 months +18
• ATM program on file since Aug 2025 +15
• Shelf registration (S-3ASR, Jun 2026) +10
• Share count +25% in a year +14

Recent financing filings on SEC EDGAR:

• Jun 18, 2026 · Shelf registration, up to $90M · S-3ASR
• Aug 22, 2025 · ATM program, up to $350M · 424B5
• Feb 21, 2024 · Underwritten offering · 424B5

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IOVA files for a raise →

👥 Who Owns IOVA

Share count 452,971,432 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.